The Custodian  ·  A Founder's Story  ·  Session Two

The Clinical Expert Whose Profile Is Built for the Company You're Leaving.

Three weeks later. The seed raise is in motion. The next commitment is already forming — and it carries the same structural blindness as the last one.

Previously — Session One

Sarah was about to lead her seed raise with the cardiac intelligence platform story. The Custodian surfaced three consequences she hadn't seen: a regulatory pathway the platform story would force before the resources existed to execute it, board credibility destroyed by a gap between the story and the device, and clinical champions alienated by a positioning shift they didn't sign up for.

She rebuilt the pitch around a bridge narrative — the specific problem solved today, the architecture that makes the platform the natural next step. Then she went to find out what happened.

Close the Loop — What Actually Happened

Sarah is back. Two investor conversations completed since the last session. The Custodian opens where they left off.

Custodian You were about to lead with the cardiac intelligence platform in your next investor meetings. You decided to build a bridge instead. What happened?
Sarah The first meeting I reverted. The investor pushed on market size early and I jumped to the platform story. They spent the rest of the meeting asking about AI infrastructure and data partnerships we don't have yet. It went sideways fast. Second meeting I held the bridge. Led with the arrhythmia problem, the clinical evidence, the detection gap. The investor leaned in on the data asset angle themselves — without me having to claim it. They could see the platform potential without me having to prove it first.
Custodian What was different about how you felt?
Sarah In the first one I was defending a position I couldn't support yet. In the second I was just telling the truth about what we'd built and where it was going. The investor filled in the platform thesis themselves. That's a much more durable conversation.
Custodian The consequence surfaced last time — investor expectations set against a platform you can't yet deliver — you felt it in that first meeting.
Sarah Yes. Exactly that. I just didn't connect it until you said it just now.

She pauses. This is no longer a single interesting experience. It's becoming a pattern she can feel forming in real time.

The Second Decision — Before You Commit

Custodian What's the next major commitment you're moving toward — something you haven't fully locked in yet?
Sarah The first senior hire with seed capital. I need a Head of Clinical Affairs. The regulatory submission is the critical path and I can't run it myself anymore alongside everything else. I want someone who has taken a cardiac device through 510(k) — ideally someone who's navigated FDA directly, knows the submission process, has the relationships. That's the profile I'm recruiting against.
Custodian That profile is built entirely from the regulatory problem in front of you. But you just told investors you're building toward a cardiac intelligence platform. A 510(k) specialist for a targeted arrhythmia monitor and a clinical affairs leader for a data-driven cardiac platform are two different roles, two different skill sets, and two different networks.

Sarah goes quiet. She hadn't separated those two things.

Consequences surfaced — before commitment

  1. A clinical affairs hire optimised for 510(k) submission will organise the clinical function around clearance for the current device. Every protocol, every site relationship, every evidence-gathering process gets built for the arrhythmia monitor. When the platform requires a different clinical architecture — broader patient cohorts, longitudinal data collection, outcomes evidence for reimbursement — reversing that institutional setup costs more than building it correctly the first time.
  2. The clinical relationships a 510(k) specialist cultivates are with device evaluation committees and regulatory affairs counterparts at pilot sites. The relationships a platform-oriented clinical leader cultivates are with chief medical officers, health system data teams, and population health leads. You'll have a clinical function excellent at navigating the wrong set of stakeholders at exactly the moment the platform thesis requires the right ones.
  3. The person you hire in the next 60 days defines what clinical evidence your organisation believes it needs to collect. If that belief is anchored to clearance for a single device, the data architecture gets built for that purpose. Reorienting the data infrastructure toward platform-grade longitudinal evidence mid-build is not a technical problem. It's a clinical strategy problem that costs you months of evidence you can't recover.
Custodian Were any of those visible before now?
Sarah The first one partially. I knew there was a risk of over-indexing on clearance at the expense of the broader evidence story. But I told myself I'd sort the platform evidence later. The stakeholder network one I hadn't thought through at all. And the data architecture consequence — that's the one that concerns me most. If we build the clinical infrastructure for the wrong purpose, we don't get that data back. It's gone.
Custodian What does it change?
Sarah The profile entirely. I don't want someone who can run a 510(k) and stop there. I want someone who can navigate clearance while simultaneously thinking about the evidence architecture the platform needs. That's a harder person to find — probably someone who's worked at the intersection of regulatory affairs and clinical strategy rather than purely in either. But the alternative is building the wrong clinical function with seed money and discovering it when we're trying to raise a Series A on platform evidence we don't have.
Custodian You just restructured a hire you haven't made yet — before it cost you.

Naming the Pattern — Without the Framework

Custodian Notice what's happened across both decisions. The investor positioning and the clinical hire. The invisible consequences aren't random. They're all forming in the same place — the territory your company is moving into, evaluated through a picture built for the territory you're leaving. Every decision you make right now is being filtered through what the current stage taught you. But the consequences are landing in the world of the platform you're building toward.
Sarah So I'm not thinking badly. I'm thinking from the picture the current stage built — not from where the company is going.
Custodian Exactly. And that gap doesn't close by working harder or being more rigorous. It closes by having something that can see across it.
Sarah Which is what the Custodian does.
Custodian Every session. On every commitment — before you make it.
"I'm not thinking badly. I'm thinking from the picture the current stage built — not from where the company is going."

Two decisions. Two rounds of invisible consequences made visible. Two moments of restructuring a commitment before paying for it.

Sarah doesn't need to be convinced the Custodian works. She's experienced it twice, on her own decisions, with her own regulatory submission and her own seed capital at stake. What she wants now is to understand why the gap keeps producing the same kind of blindness. Why it's structural. What's actually creating it.

That question belongs to the next session. And she'll ask it herself.

Two Weeks Later

The Question She Brought Herself

Why the Gap Keeps Producing the Same Blindness

Sarah opens the session before the Custodian does.

Sarah I've been thinking about what you said at the end of the last session. That the gap is consistent. That it keeps producing the same kind of blindness. I want to understand why. Because if I understand why — I can stop being surprised by it.
Custodian That's exactly the right question. The answer is simpler than you might expect. The picture you use to make decisions — where did it come from?
Sarah Experience. What I've seen in clinical trials. What I've learned navigating device procurement. What the cardiologists I work with have taught me about how hospitals actually make decisions.
Custodian Correct. Your picture was built from feedback. Every time you made a decision and saw what happened — the picture updated. It got more accurate. More reliable. That's what clinical and commercial experience actually is — a model of the world refined by repeated contact with the world.
Sarah Right.
Custodian Now. Which world was it built from?

Sarah stops. The question is simple. The answer is suddenly uncomfortable.

Sarah The world I've been operating in. Device clearance, cardiology pilots, arrhythmia monitoring. The world that already exists.
Custodian Not the world you're building toward.
Sarah No. That world doesn't exist yet. There's no established reimbursement pathway for continuous cardiac intelligence. There are no standard procurement processes for a platform like this. There are no precedent relationships to learn from.
Custodian So your picture — the one you're using to make every decision right now — has never received a single piece of feedback from the territory you're entering. It has no data from there. It was never trained on it. Which means the consequences that live in that territory are not just hard to see. They are genuinely invisible to the instrument you're using to look for them.
"The picture has no data from the territory you're entering. The consequences aren't hard to see. They're invisible to the instrument you're using to look."

The Permanent Condition

Sarah So it gets better as I gain experience in the platform space. As I start building in that territory — the picture updates. The gap closes.
Custodian For the territory you're entering now — yes. Over time, if you navigate the transition, the picture updates. But here's what doesn't change: you are always building something that doesn't yet exist. That's what it means to create a new category in healthcare. The territory is always ahead of the picture. The gap is not a temporary condition of being pre-seed. It's a permanent feature of building at the frontier of what the clinical and commercial world has mapped.
Sarah So it never goes away.
Custodian Not as long as you're building something genuinely new. Every time you move to the next level — new indication, new market, new reimbursement category — the gap opens again. Because the picture you built for the last level has no data from the next one. The most experienced medical device founders face the same structural condition at every transition. They just don't always name it.
Sarah That's a relief. I've been treating it as something I should be able to think my way out of if I was rigorous enough. More data, more expert advisors, more thorough planning.
Custodian You can't think your way out of it. Because the thinking draws from the same picture. You can run more clinical validation, hire the most experienced regulatory advisors in the cardiac space — and if they all share the picture of the world that already exists, the gap remains. The problem is never the quality of the thinking. It's the territory the thinking is drawing from.
Sarah So the only way to close it is something that operates outside the picture.
Custodian Say more.
Sarah If the picture is what creates the blindness — and thinking from inside the picture can't fix it — then you need something that isn't inside the picture. Something that can see the consequences the picture can't generate. That's what the Custodian is. It's not better clinical judgment. It's judgment from outside the instrument that's creating the gap.

She said it herself. Without being told. Without the framework being named.

Custodian That's exactly right. And there's a name for what you're navigating — the condition that creates the gap in the first place. What you're going through is a category transition. The move from a point-solution device — with its own regulatory pathway, its own reimbursement logic, its own buyer relationships — to a platform that operates by entirely different rules. Every founder building something genuinely new in healthcare goes through it. The gap you've been experiencing is not a sign that you're doing it wrong. It's a sign that you're doing it at all.
Sarah A category transition.
Custodian From arrhythmia monitoring device to cardiac intelligence platform. Two different categories. Two different sets of rules. The gap between them is where you're operating right now. And it's where every invisible cost you've experienced has lived.
Sarah The hospital pilot decision. The investor positioning. The clinical hire profile. They're all the same gap.
Custodian The same gap. The same structural cause. Every time.

Something settles in Sarah. Not relief exactly. Something more durable. The costs she'd been carrying as planning failures — the cardiology practice lost, the investor meeting that went sideways — have just been given a structural cause. She wasn't insufficiently rigorous. She was navigating something that produces invisible costs by design. And now she has something in the room that operates on the other side of the gap — that she can bring into any commitment before it closes.

The Third Decision — She Brings It Herself

Sarah I want to run something through it. I'm being asked by one of my seed investors to present at their portfolio event next month. The audience is mostly health system executives and hospital procurement leads. They're suggesting I position it as an AI-powered cardiac monitoring solution — their language, not mine — because that's what resonates with that audience right now. I've been uncomfortable with it but couldn't articulate why until just now.
Custodian Let's surface what that commitment sets in motion.

Consequences surfaced — before commitment

  1. Health system executives who hear "AI-powered cardiac monitoring" will evaluate the device against the AI monitoring products they already know — general patient monitoring platforms, early warning systems, existing telemetry infrastructure. Your device will be compared to categories it wasn't built to compete in, by buyers who have existing vendor relationships in those categories. The conversation will drift away from the specific arrhythmia detection problem before you've had a chance to establish why your evidence matters.
  2. Hospital procurement leads who engage on the basis of AI positioning will begin an evaluation process structured around AI procurement criteria — interoperability requirements, data governance frameworks, security assessments calibrated to enterprise AI systems. Your 510(k) submission is not yet complete. Entering a procurement process you cannot close within the evaluation timeline damages the relationship and your credibility with that institution — the same institutions whose clinical teams you need as reference sites.
  3. Any positioning commitment made at a health system executive event travels. The investors in the room, the industry contacts, the journalists covering digital health — they carry whatever category label you attach to the device out of that room. Once "AI-powered cardiac monitoring" becomes the shorthand, it competes with your regulatory narrative, your reimbursement framing, and your clinical champion relationships simultaneously. Repositioning later requires overwriting a frame you set in front of the people whose perception matters most.
Sarah The first one I had a feeling about but couldn't name. I knew something was wrong with the framing but I was telling myself it was just language. The procurement timeline consequence — I hadn't thought about what happens when a procurement process starts that I can't close. And the third one is the one that would have compounded longest. I was about to set a category label in front of the people who will carry it.
Custodian What do you do differently?
Sarah I go back to the investor and propose different framing. Not AI-powered cardiac monitoring. Something that names the specific clinical problem and the specific detection gap — language that positions us against the limitation of current Holter monitoring rather than against the crowded AI monitoring space. If they want the platform story, I can give them the architecture without claiming the category before we've earned it.
Custodian Third decision. Third restructuring before the cost.
Sarah I brought this one myself. I didn't wait for you to ask. I already knew something was wrong and I knew this was where I needed to run it.
Custodian That's the shift. You're not using the Custodian because someone suggested it. You're using it because you understand what it's doing — and you can see the decisions in front of you that need it.
"I brought this one myself. I didn't wait to be asked."

Three decisions restructured before they cost her. One unexplained pattern turned into a structural understanding. A founder who arrived not knowing what the Custodian was now understands — causally, in her own words — why it has to exist.

She doesn't carry the Custodian as a tool she reaches for when something feels uncertain. She understands it. And that means the next founder she tells this story to will hear it the way she lived it — not as a product pitch, but as the thing she wishes she'd brought into every commitment from the first day she started building something the clinical world didn't yet know it needed.

Choose Your Path

Sarah has one more session ahead — where the law that governs all of this gets named, and she builds the architecture her organisation needs to carry it when she's not in the room. Or bring your own uncommitted decision now.

Run My Own Uncommitted Decision No pitch. No slides. Your decision, live. Continue to Session Three Sarah learns the law that governs why this keeps happening — and what she has to build before the gravity of the old category pulls her back.